It is important to use the latest information on BNF for clinical decisions. The BNF printed edition is updated every year in March and September. Monthly updates are provided online through Medicines Complete and the NHS Evidence Portal. More important changes are in the Changes section; The changes are listed on the Internet as cumulative (from one printed edition to the next) and can be printed monthly to reflect major changes since the last print as an auxiliary book for those who use the printed version. It is best known for covering Harvard-style referencing, in the format used by most of the programmes on campus, but is also covers other styles, including Vancouver, a style used by some Pharmacy students. Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.

In the body of your text, an indication of where the information for a specific sentence or quote comes from. Depending on which referencing style you use, this might be the name of the author of the information source and the year it was written, or it might be a number. For example, Harvard uses author and date, whereas Vancouver uses a number system. Reference list Therapeutic equivalence g Biosimal drugs should be considered therapeutically equivalent to the original biological drug within their permitted designations. h Biosimal drugs are generally licensed for all indications of biological drug development, but are subject to evidence submitted to the EMA for approval and must be scientifically substantiated by proven or extrapolated agreement. Prescribing and administering The choice of prescribing a biosimal drug or a drug of biological origin is up to the physician in consultation with the patient. g Biological drugs (including biosimal drugs) must be prescribed and labeled to prevent prescription. Automatic label exchange at the point of delivery is not suitable for biological medicines. Shortened to subtitles Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice] National Institute for Health and Care Excellence (2020) Acute coronary syndromes. NG185. Available at:https://www.nice.org.uk/guidance/ng185(Accessed: 7 December 2020). Joint Formulary Committee (2021) 'Paracetamol', in British National Formulary. Available at: https://www-medicinescomplete-com.apollo.worc.ac.uk/#/content/bnf/_970446495(Accessed: 21July2022).Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is issued under the auspices of a Joint Formulation Committee composed of representatives of two professional bodies, the British Health Departments, the Agency for the Regulation of Medicines and Medical Products and the manufacturer of national guidelines. Dental Advisory Group oversees the preparation of dental and oral treatment management advice; the group includes representatives of the British Dental Association and representatives of the British Health Departments. The Prescribing Physicians Advisory Group provides advice on nurse-related content and includes representatives from different parts of the nursing community and the UK's health departments. As an example, here's a reference for the whole print BNF in Harvard format (remember, though, that you will probably be referencing a specific entry):

Biologics, Biosimilars and Biobetters: An Introduction for Pharmacists, Physicians and other Health Practitioners(2021) An integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care. If unprotected ("generic") names are provided, they should be used in prescribing. This allows any suitable product to be delivered, thus saving patient delays and sometimes healthcare costs. The only exception is when there is a difference in clinical effect between each version of the product, which is important so that the patient always receives the same brand; in such cases, the brand or manufacturer name must be given. Non-proprietary names should not often be devised for prescribing, as this can lead to confusion, especially in the case of compound and controlled release products. Livtencity® [maribavir] for cytomegalovirus disease in recipients of haematopoietic stem cell transplant or solid organ transplantJoint Formulary Committee (2021) British National Formulary, 81, March-September 2021. London: BMJ Group and Pharmaceutical Press.